论文部分内容阅读
目的:探讨沙格列汀联合阿卡波糖治疗初诊老年2型糖尿病的临床效果。方法:在医院2015年2月到2016年3月期间诊治的初诊老年2型糖尿病患者中抽取78例作研究对象,并遵循随机抽签原则分组,治疗组(n=39)应用沙格列汀联合阿卡波糖治疗,对照组(n=39)单纯使用阿卡波糖治疗,对比两组患者用药前后糖化血红蛋白变化以及低血糖反应发生率。结果:①治疗组治疗后的血红蛋白水平低于对照组(P<0.01);②治疗组患者低血糖反应发生率是5.13%,低于对照组患者的20.51%(P<0.05)。结论:沙格列汀联合阿卡波糖治疗初诊老年2型糖尿病的临床效果肯定,可明显降低患者血糖水平,其用药安全性较高,值得借鉴。
Objective: To investigate the clinical effect of saxagliptin plus acarbose in the treatment of newly diagnosed type 2 diabetes in elderly patients. Methods: Seventy-eight patients with newly diagnosed type 2 diabetes mellitus who were diagnosed and treated during the period from February 2015 to March 2016 in the hospital were enrolled in this study. Patients were randomly divided into two groups. The treatment group (n = 39) Acarbose treatment, the control group (n = 39) Acarbose treatment alone, before and after treatment in patients with glycosylated hemoglobin changes and the incidence of hypoglycemia. Results: ① The hemoglobin level in the treatment group was lower than that in the control group (P <0.01). ② The incidence of hypoglycemia in the treatment group was 5.13%, which was lower than that in the control group (20.51%, P <0.05). Conclusion: Saxagliptin combined with acarbose in the treatment of newly diagnosed type 2 diabetes in elderly patients affirms the clinical effect, which can significantly reduce the blood sugar level of patients with high safety of medication, it is worth learning from.